🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Application of Ultra-high Frequency Ultrasonography (UHFUS) to the Study of Gingival Tissues

Recruitingn/aAges 18 Years - 70 YearsAllUniversity of Pisa
NCT06480825 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Gingival inflammation triggered by the accumulation of bacterial is the primary risk factor for the development of periodontitis. Clinically, localized signs of inflammation limited to the gingiva, presence of significant bacterial plaque load, and stable attachment levels on the periodontium can be observed in course of gingivitis. The aim of the present study is to compare clinical aspects of gingival tissue in healthy patients versus patients with gingivitis to assess the ultrastructural variations present in course of inflammation. Patients with gingivitis and healthy controls will be enrolled. All patients will undergo ultra-high frequency ultrasonographic scans (70 MHz) of gingival tissue on three areas per dental arch (anterior, middle right, middle left). Gingival thickness, echogenicity, and vascularization assessed through resisitive index will be evaluated.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * males or females of age \> 18 years * presence of at least 20 teeth * full-mouth plaque score (FMPS) \>50% * FMBS \>30% * ability and willingness to give informed consent Exclusion Criteria: * pregnancy or breastfeeding * pharmacological treatment with antinflammatory drugs, statins, or either local or systemic antibiotics (within the previous 30 days) * smoking habit * dental or periodontal condition requiring immediate treatment * refusal to be enrolled in the study
💊

What it tests

  • Performance of ultrasonographic scan
📍

Where

2 sites
University of Pisa
Pisa, Italy
Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University Hospital of Pisa
Pisa, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy